lipo-5
Vaccineexperimental
Clinical trial activity
3 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2004 (NCT00076063)
Timeline
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- lipo-5
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02038842 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2014 | CHU Henri Mondor, French National Agency for Research on AIDS and Viral Hepatitis |
| NCT00121758 | Phase 2 | Sep 1, 2004 | Aventis, French National Agency for Research on AIDS and Viral Hepatitis, University of Paris |
| NCT00076063 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2004 | City of San Francisco, Government of France, National Institute of Allergy and Infectious Diseases (NIAID), St. Louis University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| French National Agency for Research on AIDS and Viral Hepatitis | Government | 2 | 2 | 1 | 2004 |
| Aventis | For profit | 1 | 0 | 1 | 2004 |
| CHU Henri Mondor | Academic/Hospital | 1 | 0 | 1 | 2014 |
| City of San Francisco | Government | 1 | 0 | 1 | 2004 |
| Government of France | Government | 1 | 0 | 1 | 2004 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2004 |
| St. Louis University | Academic/Hospital | 1 | 0 | 1 | 2004 |
| University of Paris | Academic/Hospital | 1 | 0 | 1 | 2004 |
8 organizations
Page 1 / 1